Target Price Playground
GSK
$47.76
Swing & Horizon Engine
Need pre-expiry P&L (+3d / +5d), multi-leg ratios, or hedged overlays on GSK? Launch with your exact active legs & +-12.0% target.
โก Quant Efficiency Alert: Bear Put Spread Delivers
+219.8% ROI
vs
+172.5% ROI
on Long Put at $42.03 Target
Bear Put Spread cuts entry cost by 15% ($187 vs $219), lowers breakeven to $46.13 (-3.4%), and slashes daily theta burn from $1.69/d to $0.80/d.
Forward Projection
If price hits $42 by Jan 15
Multi-Option Simulator
Pre-expiry +3d/+5d & Overlays
Options Architect
Multi-leg solver & Greeks
1x1x1 Structure
Reverse Time-Diagonal + Call
๐ Strategy
Long Stock
Long Call
Long Put
Bull Call Spread
Bear Put Spread
Bear Call Credit Spread
Bull Put Credit Spread
Covered Call
Protective Put
Cash-Secured Put
Diagonal Put Spread
Long Straddle
Bearish. Max profit if underlying crashes, capped loss.
๐ฏ Target
1-Click Institutional Target Anchors:
56d from today
โ๏ธ Legs
LONG PUT ยท $48 ยท Jan '27
Qty 1 ยท Premium $2.19 ยท ฮ -0.47
P&L at Expiry
Stock (100 sh)
Long Put
Now
Target
๐ก Stock vs Options at Target
If GSK hits $42 by Jan 15: the long put returns +$378 (172.5%) on $219 risked, vs $-573 (-12.0%) for 100 shares on $4,776. Options give 14.4ร capital efficiency.
๐ Expiry & Gamma Wall Alignment
Options expire Jan 15, 2027 (56 days out). P&L shown is the value at expiry if GSK is at $42.
๐ Projected Return
P&L if GSK hits $42 by Jan 15
+$378
+172.5% on $219 risked
Max Profit
+$4,581
If stock โ $0
Max Loss
โ$219
Premium paid
Break-even
$45.81
-4.08% from spot
Prob. of Profit at Expiry (PoP)
36.1%
Below breakeven ($45.81)
ยท Touch Target: 31%
30-Day Theta Burn (If Flat)
โ$51
23.3% of entry cost ยท Daily ฮ: $-1.69/day
Net ฮ / ฮ / V
-47.02 / -1.69 / 7.44
per spread, per $1 move / day / vol pt
๐ P&L Scenarios โ what happens at different prices and dates
| GSK Price | Today | +3d (Nov 23) | +7d (Nov 27) | Dec 8 | Dec 27 | Jan 15 (exp) |
|---|---|---|---|---|---|---|
| $38 (-20%) | +$733 | +$734 | +$735 | +$739 | +$749 | +$760 |
| $41 (-15%) | +$508 | +$508 | +$507 | +$507 | +$511 | +$521 |
| $42 (-12%) โ target | +$383 | +$381 | +$379 | +$374 | +$370 | +$378 |
| $43 (-10%) | +$305 | +$303 | +$300 | +$291 | +$279 | +$283 |
| $45 (-5%) | +$133 | +$129 | +$123 | +$106 | +$72 | +$44 |
| $47 (-2%) | +$48 | +$44 | +$37 | +$16 | -$28 | -$99 |
| $48 (0%) โ spot | -$0 | -$5 | -$12 | -$34 | -$82 | -$195 |
| $49 (+2%) | -$42 | -$47 | -$54 | -$76 | -$125 | -$219 |
| $50 (+5%) | -$93 | -$98 | -$105 | -$126 | -$169 | -$219 |
| $53 (+10%) | -$152 | -$156 | -$161 | -$177 | -$205 | -$219 |
| $55 (+15%) | -$186 | -$189 | -$192 | -$202 | -$216 | -$219 |
| $57 (+20%) | -$204 | -$205 | -$208 | -$213 | -$219 | -$219 |
Uses GSK's current IV for repricing. P&L includes all legs (stock + options). Qty: 1x.